We Learned?
J.M. M
EKEL, A.S. T
HORNTON, D.A.M.J. T
HEUNS, L.J. J
ORDAENSBackground
Persistent atrial fibrillation represents a management problem for the physi- cian and a condition associated with considerable morbidity. The results of anti-arrhythmic therapy are disappointing [1]. In the 1980s the rapid devel- opments in implantable device technology, combined with the knowledge that atrial defibrillation thresholds were far lower with internal cardiover- sion than with transthoracic cardioversion [2] and the rationale for applying early cardioversion of atrial defibrillation to limit electrical remodelling, led to the development of the implantable atrial defibrillator or atrioverter. The first commercially available device was only capable of delivering low-energy shocks, specifically for atrial defibrillation; later, high-energy devices became available that could accomplish atrial and ventricular defibrillation.
Electrode configurations are variable, with shock coils positioned in the right atrium and coronary sinus or only in the right ventricle or different combinations.
Stand-Alone Atrial Defibrillators
The InControl Metrix Atrioverter system (Guidant Corp., St Paul, Minn., USA) consists of an implantable atrial defibrillator connected to right atrial and coronary sinus defibrillation leads and a right ventricular pacing lead (Fig. 1). It is capable of delivering a maximum of 6 J of energy. This system was evaluated acutely in a study of 51 patients [3] and demonstrated the
Department of Electrophysiology, Erasmus Medical College, Rotterdam, The
Netherlands
capability of the device to deliver promptly and safely internal shocks for the acute treatment of recurrent episodes of atrial fibrillation. These patients were subsequently also evaluated in the ambulatory setting [4].
Dual-Chamber Defibrillators
A number of implantable cardioverter defibrillators (ICDs) capable of deliv-
ering shock therapy for atrial and ventricular tachyarrhythmias have been
developed, including the Jewel AF model 7250 ICD and GEM III AT
(Medtronic, Inc., Minneapolis, Minn., USA), and the Prizm AVT and Vitality
AVT (Guidant Corp., St Paul, Minn., USA). In addition, these devices can
deliver overdrive pacing therapy in the atrium which may obviate the need
Fig. 1.Chest radiograph of a patient with an implanted atrioverter with leads in the right
atrium, the coronary sinus, and the apex of the right ventricle. The right atrial and coro-
nary sinus leads are used for arrhythmia recognition and defibrillation. The right ven-
tricular lead is used for shock synchronisation and, if needed, ventricular pacing
to administer a shock. The largest amount of data published has been on the Jewel AF, a dual-chamber defibrillator also capable of delivering preventive pacing therapies and atrial overdrive pacing. It delivers a maximum of 27 J of electrical energy. This device is combined with pace-sense electrodes in the right ventricle and atrium together with one ventricular and one supraventricular shocking electrode and an optional third high-voltage elec- trode in the coronary sinus. It may be employed as an active can device or subcutaneous patches may be added. The device uses algorithms to distin- guish between atrial tachycardia, atrial fibrillation, and ventricular tach- yarrhythmias. It may be programmed to deliver atrial shock therapy auto- matically (Fig. 2) after a variable interval or only in response to a patient- initiated request given by means of a manual activator. The former program- ming allows for automatic shocks to be delivered at a moment when the patient is least likely to experience it as painful, uncomfortable, or inconve- nient; the latter programming allows the patient to optimise conditions for delivery of the shock, including taking a sedative or analgesic prior to shock delivery. To minimise the risk of inducing a ventricular tachyarrhythmia the device synchronises the shock with an R wave and will only deliver therapy after a relatively long R-R interval, nominally 500 ms in this device. This device was evaluated in the Worldwide Jewel AF-Only Trial [5].
Safety and Efficacy of Cardioversion of Atrial Fibrillation by Implantable Devices
In the study by the Metrix investigators [3] the device delivered a total of 670 shocks for 227 spontaneous episodes of AF in 41 patients during a mean fol- low-up of 259 days (2 SD = 138 days). A further 3049 shocks were delivered for induced episodes of AF during testing of the synchronisation adequacy
Fig. 2. Intracardiac electrogram and a marker channel showing the detection and shock termination of an episode of atrial tachycardia in a Jewel AF dual-chamber defibrillator.
TF interval below atrial tachycardia detection interval, TD atrial tachycardia detection, AS atrial sensed event, VS ventricular sensed event